A Phase 3, Long-term Safety Study of LY3502970 in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone or in Combination With Oral Antihyperglycemic Medications (ACHIEVE-J)
Latest Information Update: 17 Oct 2024
At a glance
- Drugs Orforglipron (Primary) ; Antihyperglycaemics
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Registrational
- Acronyms ACHIEVE-J
- Sponsors Eli Lilly and Company
Most Recent Events
- 11 Oct 2024 Planned End Date changed from 21 Jun 2025 to 1 Jun 2025.
- 11 Oct 2024 Planned primary completion date changed from 21 Jun 2025 to 1 Jun 2025.
- 14 Jun 2024 Status changed from recruiting to active, no longer recruiting.